Benzatropine
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
- Benzatropine
- Benzatropine: From Parkinson Disease to PLA2G6-Associated Neurodegeneration
- Supplementary Prediction: Attention Deficit-Hyperactivity Disorder
Benzatropine: From Parkinson Disease to PLA2G6-Associated Neurodegeneration
One-Sentence Summary
Benzatropine is an anticholinergic medicine originally used for Parkinson disease and related parkinsonian and dystonic movement disorders. The TxGNN model predicts it may be effective for PLA2G6-associated neurodegeneration, but currently there are 0 clinical trials and 0 publications supporting this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Parkinson disease and related parkinsonian and dystonic disorders (approved indication text is not listed in the Singapore licence records; this is taken from the knowledge-graph indication list) |
| Predicted New Indication | PLA2G6-associated neurodegeneration |
| TxGNN Prediction Score | 99.17% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available. Based on known information, benzatropine is an anticholinergic agent already used for parkinsonism and dystonic symptoms. Its efficacy in these conditions suggests it may mechanistically be applicable to similar symptoms in the predicted new indication.
PLA2G6-associated neurodegeneration includes infantile neuroaxonal dystrophy and PLA2G6-related dystonia-parkinsonism (PARK14). The model may be propagating signal from the shared parkinsonian and basal ganglia features. If benzatropine worked here, it would only relieve symptoms such as rigidity, tremor or dystonia. It would not slow the disease.
Anticholinergic burden is also a concern in a neurodegenerative population, because cognitive and autonomic adverse effects could worsen the clinical picture. The high score is a graph-based prediction and has not been verified by any study.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16222P | Benzatropine Phebra Solution for Injection 2 mg/2 mL | Injection, solution | Not stated in the records |
| SIN05894P | Apo-Benztropine Tablet 2 mg | Tablet | Not stated in the records |
Safety Considerations
- Contraindications flagged in the knowledge graph (these come from disease-level links, not from package insert text):
- Eye: open-angle glaucoma, angle-closure glaucoma, closed-angle glaucoma
- Gastrointestinal: paralytic ileus, achalasia, megaesophagus, hiatus hernia, ulcerative colitis, inflammatory bowel disease, Clostridium difficile colitis, perinatal necrotizing enterocolitis, gastric ulcer
- Neuromuscular: myasthenia gravis and neuromuscular junction disease
- Cardiovascular: hypertension, hypotension, coronary artery disease, heart conduction disease, sudden cardiac arrest
- Other: benign prostatic hyperplasia, chronic obstructive pulmonary disease, kidney disease, liver disease, gallbladder disease
- Drug Interactions: 78 interactions are recorded. The main ones are:
- Major: potassium chloride and potassium citrate
- Moderate: other anticholinergics (atropine, hyoscyamine, dicyclomine, glycopyrronium, clidinium, propantheline, methscopolamine, mepenzolate), opioids and related drugs (morphine, opium, loperamide, eluxadoline), cannabinoids (dronabinol, nabilone), metoclopramide, and pramlintide
Stacking anticholinergics adds to the overall anticholinergic burden.
Please also refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high, but there are no clinical trials or publications and the evidence level is L5 (model prediction only). Any benefit would be symptomatic at best, and the anticholinergic burden is a particular concern in a neurodegenerative population.
To proceed, the following is needed:
- Mechanism of action data for benzatropine
- Package insert warnings and contraindications from the HSA website
- A literature and trial search for benzatropine in PLA2G6-associated neurodegeneration, including PARK14 dystonia-parkinsonism
- Evidence that symptomatic anticholinergic treatment helps this patient group
- A safety plan covering cognitive and autonomic adverse effects and interacting drugs
- A check of route compatibility for the injection and tablet forms
Supplementary Prediction: Attention Deficit-Hyperactivity Disorder
The second-ranked prediction is attention deficit-hyperactivity disorder (TxGNN score 99.03%, evidence level L5, decision Hold). It has no clinical trials and no literature in the compiled data.
A speculative link is that benzatropine modulates the balance between cholinergic and dopaminergic signalling in the striatum. This is not verified, and the mechanism of action data is not available. Central anticholinergics can impair attention and memory, which argues against benefit in ADHD. Misuse potential and the 78 recorded drug interactions are further concerns, especially alongside stimulants and other CNS-active drugs. This prediction should not be pursued without new supporting evidence.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.